Abraham, M
Klein, S
Bulvik, B
Wald, H
Weiss, I D
Olam, D
Weiss, L
Beider, K
Eizenberg, O
Wald, O
Galun, E
Avigdor, A
Benjamini, O
Nagler, A
Pereg, Y
Tavor, S
Peled, A
Article History
Received: 21 October 2016
Revised: 24 February 2017
Accepted: 1 March 2017
First Online: 10 March 2017
Competing interests
: Michal Abraham, Hanna Wald and Orly Eizenberg are employees and shareholders of Biokine Therapeutics; Amnon Peled serves as a consultant for Biokine Therapeutics and is also a shareholder. Yaron Pereg is an employee of BioLineRx. Remaining authors declare no conflict of interest.